Related Content
Download content relating to this event and topic.
The only European meeting focused on solving the toughest translational barrier in ADC development: moving potent linker–payload candidates into scalable, CMC-ready clinical products
ADC Connect 2025 is the only European meeting focused on solving the toughest translational barrier in ADC development: moving potent linker–payload candidates into scalable, CMC-ready clinical products.
This is not a siloed chemistry forum. It’s a strategic, cross-functional gathering of antibody engineers, translational teams, and bioconjugation leaders - all working to bridge the gap between preclinical promise and GMP production.
If you’re wrestling with DAR variability, payload toxicity, or scale-up complexity - you’ll find answers here.
Designed for Translation, Not Just Conjugation
Most ADC events stop at chemistry. We go further; focusing on the core challenge of turning potent, unstable linker–payload systems into scalable, CMC-ready therapeutics.
True Cross-Functional Dialogue
We bring together antibody engineers, translational scientists, and CMC teams to align on what makes an ADC manufacturable. That’s rare. And essential.
An Audience Who Know the Risks
You won’t be pitched hypotheticals here. Our participants are grappling with DAR variability, payload toxicity, and scale-up complexity now. And they’re looking for answers.
Strategic Exposure for Solution Providers
Vendors are embedded in the same room as early-stage engineers and manufacturing leads; a full lifecycle view of ADC development from molecule to market.
View the Key Themes for
ADC Connect 2025
Register today to secure your ticket.
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.
Dominik Brücher, CTO of CIS BIOPHARMA, is a recognized expert in protein engineering with a strong focus on biologics, including antibodies, antibody-drug conjugates (ADCs) and gene vectors. His career spans both innovative biotech ventures and large pharmaceutical organizations, where he has developed novel ADCs, particularly in the field of oncology. He also scaled a gene therapy company to over 40 employees, driving forward advanced therapeutic platforms.
Currently, Dominik leads the development of a first-in-class ADC targeting a novel oncology marker and drives the advancement of CIS BIOPHARMA’s proprietary linker-payload technology.
I am a CMC regulatory affairs professional with over fifteen years of experience in pharmaceutical research, development, and manufacturing. My journey began with a PhD in Organic Chemistry from the University of Leeds; this led to an early career in Chemical Development, focusing on commercial manufacturing route design for Pfizer’s portfolio of synthetic APIs. I have since held CMC regulatory roles at AstraZeneca, Amgen, and GlaxoSmithKline. My expertise spans synthetic products, monoclonal antibodies, biosimilars, and other complex therapies (antibody-drug conjugates, radioconjugates, bi-specific antibodies, fusion proteins) for which I have successfully led regulatory submissions and navigated global health authority requirements for both clinical and commercial assets.
Joost Uitdehaag is head of Biology at Crossfire Oncology B.V. After concluding a Ph.D. in Groningen, the Netherlands and a postdoc at the University of Oxford, he has worked for large pharma companies such as Organon, MSD and Astra-Zeneca, before shifting gears to biotech, where he worked for Oncolines, LAVA Therapeutics and now Crossfire Oncology B.V. The many projects to which he has contributed in the past include the BTK inhibitor drug acalabrutinib and the anti-PD1 antibody pembrolizumab. He currently combines his extensive discovery experience in small molecules and antibodies to generate novel protein degraders for use as payloads in antibody drug conjugates (ADCs), which have the potential to revolutionize the ADC field.
Dr Kerstin Hofer is a Senior Scientist at Roche Pharma Research and Early Development, where she leads the bioconjugation lab. She has extensive experience in the delivery of oligonucleotide-based therapeutics to target tissues, such as the brain.
Dr. Manel Kraiem Merabet is Chief Development Officer at Skymab Biotherapeutics, where she leads the development of next-generation antibody-drug conjugates (ADCs) targeting GPCRs. With over nine years of experience in translational oncology, including six years at Innate Pharma managing ADC programs from lead optimization to IND, she brings deep expertise in drug development. Dr. Kraiem Merabet holds a PharmD and PhD in Oncology and Immunology (CRCM), along with degrees in Radiopharmacy (CEA Saclay) and Organic Chemistry. She is a recognized expert and recurring speaker at the World ADC Congress.
Eef Dirksen is a protein characterization aficionado. He obtained his PhD in biomolecular mass spectrometry in 2006. Subsequently, Eef moved to Philips Research and in 2010, he was hired by MSD (Merck) in Oss, The Netherlands, where he managed a team focusing on the characterization of biopharmaceutical proteins. In this role, Eef was, amongst others, involved in the successful late-stage development of Keytruda®.
In 2015, Eef joined Byondis to work on elucidating the in vivo biotransformation of antibody-drug conjugates (ADCs). Currently, he is heading the Department of Analytical Development and Quality Control that is responsible for all analytical activities in support of early-stage CMC development of monoclonal antibodies and ADCs, providing substantial contributions to Byondis’ regulatory submissions.
Paul Sauter has a strong background in organic chemistry with a focus on synthesis and almost a decade of experience with click chemistry and holds a Ph.D. in natural sciences from the Karlsruhe Institute of Technology. He then advanced bioorthogonal click chemistry for use in nuclear medicine and antibody-drug conjugates (ADCs) during his postdoctoral studies at the EMBL. As founding team member he has since led the chemistry R&D at VERAXA, and in his current role is leading the development of VERAXA’s bioconjugation and payload platforms, the optimization for internal drug programs and further innovations towards safer ADC technologies.
Choose a plan that fits your role, company, and industry.
Priority Codes
Enter the below access codes at checkout to secure preferrential rates
EARLY-BIRD
(Valid until 18 July 2025, 23:59 BST)
TIDESxAB
(Valid until 30 August 2025, 23:59 BST)
Priority Codes
Enter the below access codes at checkout to secure preferrential rates
EARLY-BIRD
(Valid until 18 July 2025, 23:59 BST)
TIDESxAB
(Valid until 30 August 2025, 23:59 BST)
Attendance Only
Partnership benefits not included
Be the first in line! Register your interest now to get exclusive access to Super Early-Bird tickets - the lowest prices available - before they go live.
Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.
Contact the IMAPAC to learn about our sponsorship process, rates and more.
Visit the event page to view more content.
Download content relating to this event and topic.
Visit the event page to view more content.
Visit the awards page to view more content.
To stay informed about event updates, including date, venue, and agenda, please subscribe to our newsletter on our event website. You can also follow our official social media channels for real-time updates and announcements.
The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.
We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.
Yes, we have a cancellation and refund policy in place. Please refer to our “Cancellation Policy” on our website for details on how to request a refund if you are unable to attend.
We welcome presentation submissions. If you’re interested in speaking at the event, please visit this page on our website for submission guidelines and deadlines.
Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.
Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals
Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.
Yes, we offer sponsorship and exhibition opportunities for businesses and organizations. Please visit our this page on our website for more information.
To register for the event, you'll find multiple "register" buttons on this page to get started. You’ll find detailed instructions and options for registration, including pricing and deadlines.
Don't miss out on unique networking, speaking and sponsorship opportunities.